Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: A responder analysis

Rheumatology (United Kingdom)

Volumn 53, Issue 8, 2014, Pages 1457-1464

  Bruyère, Olivier ^a   Reginster, Jean Yves ^a   Bellamy, Nicholas ^b   Chapurlat, Roland ^c   Richette, Pascal ^d   Cooper, Cyrus ^e,f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITÉ DE LYON   (France)

^d UFR   (France)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Osteoarthritis; Pain; Responder criteria; Sekoia; Strontium ranelate; Symptoms

Indexed keywords

ACETIC ACID DERIVATIVE; ANALGESIC AGENT; ANILIDE; CELECOXIB; CORTICOSTEROID DERIVATIVE; LUMIRACOXIB; OPIATE; PLACEBO; PROPIONIC ACID DERIVATIVE; STRONTIUM RANELATE;

ADULT; ANALGESIA; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MINIMAL CLINICALLY IMPORTANT IMPROVEMENT; MINIMAL PERCEPTIBLE CLINICAL IMPROVEMENT; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGIDITY; SHORT FORM 36; SYSTEMIC THERAPY; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

OSTEOARTHRITIS; PAIN; RESPONDER CRITERIA; SEKOIA; STRONTIUM RANELATE; SYMPTOMS;

AGED; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; THIOPHENES; TREATMENT OUTCOME;

EID: 84904888189     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu018     Document Type: Article

References (19)

1. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115-26.
2. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
3. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001;54:1204-17.
4. Bellamy N, Bell MJ, Goldsmith CH et al. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 2005;64:881-5.
5. Pham T, van der Heijde D, Altman RD et al. OMERACTOARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99.
6. Ehrich EW, Davies GM, Watson DJ et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000;27:2635-41.
7. Tubach F, Ravaud P, Baron G et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33.
8. Reginster J-Y, Badurski J, Bellamy N et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2013;72:179-86.
9. Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
10. Cooper C, Reginster J-Y, Chapurlat R et al. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of a randomised double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28:231-9.
11. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis, 2010. www.ema.europa.eu (19 September 2012, date last accessed).
12. Sawitzke AD, Shi H, Finco MF et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459-64.
13. Burdett N, McNeil JD. Difficulties with assessing the benefit of glucosamine sulphate as a treatment for osteoarthritis. Int J Evid Based Healthc 2012;10:222-6.
14. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:1716-23.
15. White DK, Keysor JJ, Lavalley MP et al. Clinically important improvement in function is common in people with or at high risk of knee OA: the MOST study. J Rheumatol 2010;37:1244-51.
16. Pelletier JP, Kapoor M, Fahmi H et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1beta in the synovium. Ann Rheum Dis 2013;72:250-7.
17. Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J. Strontium ranelate inhibits key factors affecting bone remodelling in human osteoarthritic subchondral bone osteoblasts. Bone 2011;49:559-67.
18. Namazi H. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28:609-10.
19. Bruyere O, Delferriere D, Roux C et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9.